Eagle Bay Advisors’s Epizyme, Inc EPZM Stock Holding History

Eagle Bay Advisors’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,865	Closed	-$5K	–	1059
2021 Q4	$5K	Buy	+1,865	New	+$7.33K	﹤0.01%	813

Other funds holding EPZM

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Eagle Bay Advisors's EPZM Position: Q1 2022 in Review

Eagle Bay Advisors sold out of Epizyme, Inc (EPZM) in Q1 2022, closing a stake of 1,865 shares — an estimated $5K sold.

Eagle Bay Advisors first reported a position in EPZM in Q4 2021 and held it in 1 quarter. The position peaked at $5K in Q4 2021. 120 funds tracked by Wall St. Rank hold EPZM as of Q1 2022.

Eagle Bay Advisors reported no remaining Epizyme, Inc position as of Q1 2022 after selling out during the quarter.
Eagle Bay Advisors sold 1,865 Epizyme, Inc shares in Q1 2022, an estimated $5K.
Eagle Bay Advisors first reported a position in Epizyme, Inc in Q4 2021 and held it in 1 quarter.
Eagle Bay Advisors's Epizyme, Inc position peaked at $5K in Q4 2021.
120 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2022.

Based on Eagle Bay Advisors's 13F filing for Q1 2022, filed 11 May 2022.